长链非编码RNA MALAT-1:一种预测肿瘤转移的潜在生物标志物

Long Noncoding RNA MALAT-1:A Potential Biomarker for Predicting Tumor Metastasis

最近,越来越多的研究表明,长链非编码RNA MALAT-1在许多恶性肿瘤组织或细胞中均处于高表达状态,并与肿瘤转移关系密切。Meta分析是根据现有的研究现状对具有相同目的且相互独立的多个研究结果进行系统评价和定量分析的一种方法。在此次研究中,我们利用计算机检索维普数据库、万方数据库、CNKI数据库和Pub Med数据库,检索时间截止至2016年6月,收集所有符合纳入标准的相关研究资料。按照严格的纳入和排除标准分类整理、筛选剔除后,运用统计分析专用软件Review Manger 5.3对符合标准的研究进行Meta分析,系统评价长链非编码RNA MALAT-1的表达水平与肿瘤淋巴结转移(LNM)及远端转移(DM)之间的关系,探索MALAT-1是否具有成为预测肿瘤转移的分子标志物的潜能。初筛共检索出292篇文献,其中符合纳入标准的有9篇,应用固定效应模型或随机效应模型进行分析。研究结果表明,与肿瘤患者中长链非编码RNA MALAT-1低表达组相比,MALAT-1高表达组与肿瘤淋巴结转移(OR=2.10,95%CI:1.29~3.43,p<0.05)和远端转移(OR=2.22,95%CI:1.29~3.82,p<0.05)之间的关系密切。这说明MALAT-1的表达水平异常升高,肿瘤病人发生淋巴结转移和远端转移的危险性越大,表明长链非编码RNA MALAT-1具有成为预测不同类型肿瘤转移的分子标志物的潜能。

Recently, increasing number of studies have indicated that long noncoding RNA MALAT-1 is highly expressed in many malignant tumor tissues or cells and it is closely related with tumor metastasis. Meta-analysis is a method of systematic evaluation and quantitative analysis of multiple studies with the same purpose and independent of each other based on the existing research status. In present study, we performed a retrieval on VIP database, Wanfang database, CNKI database and PubMed database, and the retrieval deadline was set to June 2016 and we collected all relevant articles in accordance with the inclusion criteria. Published studies were classified and screened out according to strict inclusion and exclusion criteria, and calculated by Review Manager Version 5.3 for meta-analysis which was used to systematically evaluate the correlation among long noncoding RNA MALAT- 1 expression levels, tumor lymph node metastasis （LNM） and distant metastasis （DM） and explore whether MALAT-1 could serve as a predictive biomarker for cancer metastasis in different types of cancers. A total of 292 articles were retrieved after preliminary screening in which 9 eligible studies were matched to our inclusion criteria and analyzed by fixed-effect model or random-effects model. This meta-analysis showed that compared with low RNA MALAT-1 expression, high MALAT-1 expression had closer relationship with tumor LNM （OR=2.10, 95% CI： 1.29-3.43, p〈0.05） and tumor DM （OR=2.22, 95% CI： 1.29-3.82,p〈0.05）. These results indicated that the abnormal rise of MALAT-1 expression levels could result in the high risks of lymph node metastasis and distant metastasis in tumor patients, which meant that long noncoding RNA MALAT-1 had the potential to be biomarker for predicting tumor metastasis in different types of cancers.